As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.
27 Analysts have issued a Apellis Pharmaceuticals, Inc. forecast:
27 Analysts have issued a Apellis Pharmaceuticals, Inc. forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 1,016 1,016 |
42%
42%
|
|
| Gross Profit | 903 903 |
46%
46%
|
|
| EBITDA | 82 82 |
137%
137%
|
|
| EBIT (Operating Income) EBIT | 80 80 |
136%
136%
|
|
| Net Profit | 45 45 |
118%
118%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
| Head office | United States |
| CEO | Cedric Francois |
| Employees | 708 |
| Founded | 2009 |
| Website | apellis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


